ANGIODYNAMICS INC — Director's Dealing 2018

Jul 20, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2018-07-18

Reporting Person: Campbell Chad Thomas (SVP/GM, Vascular Access)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-18	Common Stock	A	3539	—	Acquired	18036	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-18	Non-Qualified Stock Option (right to buy)	$20.93	A	11276	Acquired	2028-07-18	Common Stock (11276)	Direct
2018-07-18	Performance Right	$	A	7079	Acquired		Common Stock (7079)	Direct

Footnotes

F1: This acquisition of 3,539 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,539 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.

F2: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

F3: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.